Beyond EGFR Lung Cancer Basics: Resistance, LMD & What's Next with Dr. Eric Singhi | Pt 3/3
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Beyond EGFR Lung Cancer Basics: Resistance, LMD & What's Next with Dr. Eric Singhi | Pt 3/3
-
ナレーター：
-
著者：
In the final episode of our three-part EGFR Biomarker Series, Leah Phillips of Young Lung Cancer Initiative sits down with Dr. Eric Singhi of MD Anderson Cancer Center to go beyond the basics into the topics EGFR patients ask about most.
This conversation covers small cell transformation, leptomeningeal disease (LMD), resistance mechanisms, the role of co-mutations like TP53 and RB1, and the emerging research and clinical trials shaping the future of EGFR driven lung cancer care.
Whether you've just been diagnosed or you've been living with EGFR lung cancer for years, this episode is a reminder that knowledge is power, advocacy matters, and there is real hope in this space.
Listen to Part 1 (EGFR 101) and Part 2 (Treating & Managing EGFR Lung Cancer) wherever you get your podcasts.
This series is sponsored by Johnson & Johnson. Sponsorship does not influence content. Young Lung Cancer Initiative maintains full editorial control over all educational material and patient stories.